Author:
Kuchimanchi Mita,Bockbrader Howard,Dolphin Nancy,Epling Daniel,Quinlan Lauren,Chapel Sunny,Penner Natasha
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology
Reference18 articles.
1. Doshi A, Chataway J. Multiple sclerosis, a treatable disease. Clin Med (Lond). 2016;16:s53–9.
2. Biogen: VUMERITY®(diroximel fumarate) delayed-release capsules, for oral use. 2021. https://www.vumerity.com/content/dam/commercial/vumerity/pat/en_us/pdf/vumerity-prescribing-information.pdf. Accessed 18 Nov 2021.
3. Palte MJ, Wehr A, Tawa M, et al. Improving the gastrointestinal tolerability of fumaric acid esters: early findings on gastrointestinal events with diroximel fumarate in patients with relapsing-remitting multiple sclerosis from the phase 3, open-label EVOLVE-MS-1 study. Adv Ther. 2019;36:3154–65.
4. Biogen: TECFIDERA® (dimethyl fumarate) delayed-release capsules, for oral use. 2021. https://www.tecfidera.com/content/dam/commercial/tecfidera/pat/en_us/pdf/full-prescribing-info.pdf. Accessed 18 Nov 2021.
5. Wehr A, Hard M, Yu M, Leigh-Pemberton R, von Moltke L. Relative bioavailability of monomethyl fumarate after administration of ALKS 8700 and dimethyl fumarate in healthy subjects. Neurology. 2018;90:P1.403.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献